Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 127, Issue 2, Pages 427-436Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI89786
Keywords
-
Categories
Funding
- NIH Mentored Clinical Scientist Award [K08-HL116485]
- Walker P. Inman Endowment
- Edna and Fred L. Mandel, Jr. Foundation
- NIH [R01-HL081674, R01-HL136182, R01-HL131319]
- Fondation Leducq
- American Heart Association
Ask authors/readers for more resources
Heart failure is a major source of morbidity and mortality. Replacing lost myocardium with new tissue is a major goal of regenerative medicine. Unlike adult mammals, zebrafish and neonatal mice are capable of heart regeneration following cardiac injury. In both contexts, the regenerative program echoes molecular and cellular events that occur during cardiac development and morphogenesis, notably muscle creation through division of cardiomyocytes. Based on studies over the past decade, it is now accepted that the adult mammalian heart undergoes a low grade of cardiomyocyte turnover. Recent data suggest that this cardiomyocyte turnover can be augmented in the adult mammalian heart by redeployment of developmental factors. These findings and others suggest that stimulating endogenous regenerative responses can emerge as a therapeutic strategy for human cardiovascular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available